Use of anakinra in severe COVID-19: A case report

Use of anakinra in severe COVID-19: A case report

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19...

Full description

Bibliographic Details
Main Authors:	Giovanni Filocamo, Davide Mangioni, Paola Tagliabue, Stefano Aliberti, Giorgio Costantino, Francesca Minoia, Alessandra Bandera
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	International Journal of Infectious Diseases
Subjects:	Anakinra IL-1 COVID-19 Treatment Biologic
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971220303337

Similar Items

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
by: Max Hübner, et al.
Published: (2020-02-01)

Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19
by: José A García-García, et al.
Published: (2021-09-01)

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
by: Roberto Ravasio, et al.
Published: (2020-09-01)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
by: Cristina de la Calle, et al.
Published: (2021-04-01)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
by: Annette Langer-Gould, et al.
Published: (2020-10-01)

A child with resistant Kawasaki disease successfully treated with anakinra: a case report
by: J. Sánchez-Manubens, et al.
Published: (2017-04-01)

Long-term control of refractory Schnitzler syndrome with anakinra: a case report
by: Hsien-Yi Chiu, et al.
Published: (2010-06-01)

Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis
by: Craig Davis Scoville, et al.
Published: (2017-01-01)

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra
by: Alessandro Gambacorta, et al.
Published: (2020-05-01)

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study
by: A. Balkhair, et al.
Published: (2021-02-01)

Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra
by: Manuel Alfredo Podestà, et al.
Published: (2014-09-01)

Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
by: Gaku Yamanaka, et al.
Published: (2021-06-01)

Use of Anakinra in Patients with Cryopyrin-Associated Periodic Syndromes and Other Autoinflammatory Diseases
by: Mikhail M. Kostik
Published: (2016-12-01)

The effect of anakinra on retinal function in isolated perfused vertebrate retina
by: Mahdy Ranjbar, et al.
Published: (2017-03-01)

An open label trial of anakinra to prevent respiratory failure in COVID-19
by: Evdoxia Kyriazopoulou, et al.
Published: (2021-03-01)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
by: Marco Franzetti, et al.
Published: (2020-08-01)

Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment
by: Megan E. Roerink, et al.
Published: (2017-12-01)

Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic
by: Sara Della Paolera, et al.
Published: (2021-02-01)

Use of Anakinra in steroid dependent recurrent pericarditis: a case report and review of literature
by: Vinay Kumar Thallapally, et al.
Published: (2021-07-01)

Anakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosis
by: Ángel M. Sevillano, et al.
Published: (2016-01-01)

Chronic Autoimmune Meningoencephalitis and Periodic Fever Syndrome Treated with Anakinra
by: Alyssa-Rae Novroski, et al.
Published: (2017-05-01)

Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature
by: Cinzia Marchica, et al.
Published: (2018-01-01)

Uso de antirreumáticos en covid-19 desde la hidroxicloroquina hasta la anakinra pasando por tocilizumab y baricitinib: Una revisión de la literatura
by: Salas-Bolaños, Rosa Alejandra, et al.
Published: (2021)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response
by: Seniha Başaran, et al.
Published: (2021-04-01)

Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis
by: Ángel M. Sevillano, et al.
Published: (2016-01-01)

Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen’s encephalitis
by: Monika Mochol, et al.
Published: (2021-01-01)

Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
by: Allen D. DeSena, et al.
Published: (2018-02-01)

An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment
by: Marta Mejias Trueba, et al.
Published: (2020-07-01)

Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever
by: Mustafa Çakan, et al.
Published: (2020-02-01)

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01)

Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report
by: Naina McCann, et al.
Published: (2021-01-01)

Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids
by: Paolo Cattaneo, et al.
Published: (2021-06-01)

Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra
by: Alessandra Meneghel, et al.
Published: (2021-01-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

Fatal primary dengue-induced Haemophagocytic Lymphohistiocytosis (HLH) in a returning traveller from India treated with anakinra for the first time
by: Tanmay Kanitkar, et al.
Published: (2020-10-01)

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment
by: Fréderic Franconieri, et al.
Published: (2018-08-01)

Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity
by: Marilena Pariano, et al.
Published: (2021-06-01)

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01)

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
by: Roberto Ravasio, et al.
Published: (2020-09-01)